My watch list
my.bionity.com  
Login  

52 Current news of Actelion

rss

Actelion's macitentan meets primary endpoint in pivotal Phase III study

03-05-2012

Actelion announced that initial analysis indicates that the pivotal, long-term, event-driven study SERAPHIN with macitentan, a novel dual endothelin receptor antagonist, in 742 patients suffering from pulmonary arterial hypertension (PAH) and treated for up to three and a half years, has met its ...

more

Japan's Ministry of Health, Labour and Welfare grants approval for Actelion's miglustat for the treatment of Niemann-Pick type C disease

04-04-2012

Actelion Ltd announced that Japan's Ministry of Health, Labour and Welfare has granted approval for miglustat for the treatment of Niemann-Pick type C disease.The approval was based on the data generated for the first approval of miglustat in this indication in the European Union, as well as data ...

more

Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. enter a collaboration agreement for XIAFLEX in Canada, Australia, Brazil and Mexico

Actelion obtains exclusive rights for two potential indications

24-02-2012

Auxilium Pharmaceuticals, Inc. and Actelion Ltd. announced that they have entered into a long-term partnership for the development, supply and commercialization of XIAFLEX® (collagenase clostridium histolyticum), a novel, first-in-class biologic for the potential treatment of Dupuytren's ...

more

Jean-Pierre Garnier elected as Chairman of Actelion's Board of Directors

30-09-2011

Actelion Ltd announced that Jean-Pierre Garnier has become Chairman of the Board of Directors of the Swiss biopharmaceutical company. The Board of Directors elected him at their meeting, 27 September 2011. In order to ensure a smooth transition, Robert Cawthorn, who has been Chairman since the ...

more

Actelion reports results of exploratory study with macitentan in IPF patients

30-08-2011

Actelion announced that the exploratory Phase II study with macitentan in patients with idiopathic pulmonary fibrosis (IPF) shows a promising safety and tolerability profile of macitentan, no difference being observed between placebo and macitentan with regard to liver enzyme elevations. The ...

more

Actelion announces change in its Board of Directors

04-08-2011

Actelion announced that Joseph C. Scodari - for personal reasons - has resigned from Actelion's Board of Directors at the beginning of August 2011.Robert Cawthorn, Chairman of the Board of Directors at Actelion, commented: "We would like to thank Joe for his dedication to Actelion. We have ...

more

Actelion's selective S1P1 receptor agonist ponesimod successful in mid-stage trial for multiple sclerosis

Ponesimod to proceed to Phase III final stage of clinical development

03-08-2011

Actelion announced that the primary endpoint - reduction in the number of new active inflammatory lesions in the brain - has been met with its selective S1P1 receptor agonist, ponesimod, in a Phase IIb dose-finding study in patients with relapsing-remitting multiple sclerosis.The study assessed ...

more

Actelion announces change in its management structure

Otto Schwarz appointed Chief Operating Officer

09-06-2011

Actelion Ltd announced that Otto Schwarz has been appointed Chief Operating Officer (COO). Otto Schwarz joined Actelion in 2008 as Head of Business Strategy & Operations. In addition to Commercial Operations and Business Strategy he assumes responsibility for Corporate Services, Global Quality ...

more

Actelion's novel CRTH2 antagonist meets primary endpoint in Phase II study in patients with seasonal allergic rhinitis

25-05-2011

Actelion Ltd announced that a Phase II study with its novel orally-active CRTH2 antagonist in seasonal allergic rhinitis has met its primary endpoint with statistical significance (pThe study assessed the efficacy and tolerability of various doses of this novel CRTH2 antagonist in adult patients ...

more

Jean-Pierre Garnier and Robert Bertolini nominated to join Actelion's Board

06-04-2011

Actelion Ltd announced the nomination of Jean-Pierre Garnier and Robert Bertolini for election to the Company's Board of Directors at the 2011 Annual General Meeting (AGM) of shareholders, to be held on 05 May 2011. When elected, Jean-Pierre Garnier will become a Vice Chairman together with ...

more

Page 2 From 6
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE